| Title |
Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1–31)NH2] in Postmenopausal Women with Osteoporosis
|
|---|---|
| Published in |
Clinical Pharmacokinetics, May 2013
|
| DOI | 10.1007/s40262-013-0083-4 |
| Pubmed ID | |
| Authors |
Amy Sturmer, Nozer Mehta, Jenna Giacchi, Tulin Cagatay, Roxanne Tavakkol, Sheela Mitta, Lorraine Fitzpatrick, Jeff Wald, John Trang, William Stern |
| Abstract |
Teriparatide [rhPTH(1-34)OH] is a subcutaneously administered bone anabolic drug that increases bone mineral density (BMD) and reduces the risk of osteoporotic fracture. Because rhPTH(1-34)OH is administered by injection, oral delivery is a desirable alternative. However, the peroral delivery of peptides is challenging due to their susceptibility to protease digestion and low permeability through the intestinal layers. The objective of this study was to assess the pharmacokinetics of a PTH analog (rhPTH(1-31)NH2) in a novel oral tablet formulation and to compare them to subcutaneously administered teriparatide in postmenopausal osteoporotic women in a phase 2 proof-of-concept clinical study. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 2% |
| Unknown | 54 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 20% |
| Student > Bachelor | 10 | 18% |
| Researcher | 6 | 11% |
| Student > Master | 5 | 9% |
| Other | 3 | 5% |
| Other | 5 | 9% |
| Unknown | 15 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 27% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Agricultural and Biological Sciences | 4 | 7% |
| Chemical Engineering | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 19 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2013.
All research outputs
#18,339,860
of 22,711,242 outputs
Outputs from Clinical Pharmacokinetics
#1,306
of 1,481 outputs
Outputs of similar age
#146,213
of 195,114 outputs
Outputs of similar age from Clinical Pharmacokinetics
#15
of 19 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,481 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,114 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.